Cutaneous melanoma, version 2.2019

Daniel G. Coit; John A. Thompson; Mark R. Albertini; Christopher Barker; William E. Carson; Carlo Contreras; Gregory A. Daniels; Dominick DiMaio; Ryan C. Fields; Martin D. Fleming; Morganna Freeman; Anjela Galan; Brian Gastman; Valerie Guild; Douglas Johnson; Richard W. Joseph; Julie R. Lange; Sameer Nath; Anthony J. Olszanski; Patrick Ott; Aparna Priyanath Gupta; Merrick I. Ross; April K. Salama; Joseph Skitzki; Jeffrey Sosman; Susan M. Swetter; Kenneth K. Tanabe; Evan Wuthrick; Nicole R. McMillian; Anita M. Engh

doi:10.6004/jnccn.2019.0018

Cutaneous melanoma, version 2.2019

Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Barker, William E. Carson, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Morganna Freeman, Anjela Galan, Brian Gastman, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Sameer Nath, Anthony J. Olszanski, Patrick OttAparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeffrey Sosman, Susan M. Swetter, Kenneth K. Tanabe, Evan Wuthrick, Nicole R. McMillian, Anita M. Engh

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Review article › peer-review

125 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.

Original language	English (US)
Pages (from-to)	367-402
Number of pages	36
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	17
Issue number	4
DOIs	https://doi.org/10.6004/jnccn.2019.0018
State	Published - Apr 2019

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2019.0018

Cite this

Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Fields, R. C., Fleming, M. D., Freeman, M., Galan, A., Gastman, B., Guild, V., Johnson, D., Joseph, R. W., Lange, J. R., Nath, S., Olszanski, A. J., ... Engh, A. M. (2019). Cutaneous melanoma, version 2.2019. JNCCN Journal of the National Comprehensive Cancer Network, 17(4), 367-402. https://doi.org/10.6004/jnccn.2019.0018

Coit, DG, Thompson, JA, Albertini, MR, Barker, C, Carson, WE, Contreras, C, Daniels, GA, DiMaio, D, Fields, RC, Fleming, MD, Freeman, M, Galan, A, Gastman, B, Guild, V, Johnson, D, Joseph, RW, Lange, JR, Nath, S, Olszanski, AJ, Ott, P, Gupta, AP, Ross, MI, Salama, AK, Skitzki, J, Sosman, J, Swetter, SM, Tanabe, KK, Wuthrick, E, McMillian, NR & Engh, AM 2019, 'Cutaneous melanoma, version 2.2019', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 4, pp. 367-402. https://doi.org/10.6004/jnccn.2019.0018

@article{6052851e3c7a4455b0850bb4c10b6122,

title = "Cutaneous melanoma, version 2.2019",

abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.",

author = "Coit, {Daniel G.} and Thompson, {John A.} and Albertini, {Mark R.} and Christopher Barker and Carson, {William E.} and Carlo Contreras and Daniels, {Gregory A.} and Dominick DiMaio and Fields, {Ryan C.} and Fleming, {Martin D.} and Morganna Freeman and Anjela Galan and Brian Gastman and Valerie Guild and Douglas Johnson and Joseph, {Richard W.} and Lange, {Julie R.} and Sameer Nath and Olszanski, {Anthony J.} and Patrick Ott and Gupta, {Aparna Priyanath} and Ross, {Merrick I.} and Salama, {April K.} and Joseph Skitzki and Jeffrey Sosman and Swetter, {Susan M.} and Tanabe, {Kenneth K.} and Evan Wuthrick and McMillian, {Nicole R.} and Engh, {Anita M.}",

year = "2019",

month = apr,

doi = "10.6004/jnccn.2019.0018",

language = "English (US)",

volume = "17",

pages = "367--402",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "4",

}

TY - JOUR

T1 - Cutaneous melanoma, version 2.2019

AU - Coit, Daniel G.

AU - Thompson, John A.

AU - Albertini, Mark R.

AU - Barker, Christopher

AU - Carson, William E.

AU - Contreras, Carlo

AU - Daniels, Gregory A.

AU - DiMaio, Dominick

AU - Fields, Ryan C.

AU - Fleming, Martin D.

AU - Freeman, Morganna

AU - Galan, Anjela

AU - Gastman, Brian

AU - Guild, Valerie

AU - Johnson, Douglas

AU - Joseph, Richard W.

AU - Lange, Julie R.

AU - Nath, Sameer

AU - Olszanski, Anthony J.

AU - Ott, Patrick

AU - Gupta, Aparna Priyanath

AU - Ross, Merrick I.

AU - Salama, April K.

AU - Skitzki, Joseph

AU - Sosman, Jeffrey

AU - Swetter, Susan M.

AU - Tanabe, Kenneth K.

AU - Wuthrick, Evan

AU - McMillian, Nicole R.

AU - Engh, Anita M.

PY - 2019/4

Y1 - 2019/4

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=85064408797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064408797&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0018

DO - 10.6004/jnccn.2019.0018

M3 - Review article

C2 - 30959471

AN - SCOPUS:85064408797

SN - 1540-1405

VL - 17

SP - 367

EP - 402

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 4

ER -

Cutaneous melanoma, version 2.2019

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this